CTN-0151: Toward Pharmacy-Led Value Based Care Model for Buprenorphine Initiation and Management (PharmValue): Development of a Scalable Pharmacist-Led Collaborative Practice Agreement for Medication for Opioid Use Disorder

May 8, 2024 /

Kenneth Hohmeier, PharmD
Co-Principal Investigator
University of Tennessee Health Science Center
khohmeie@uthsc.edu

Rachel Barenie, PharmD, JD, MPH
Co-Principal Investigator
University of Tennessee Health Science Center
rbarenie@uthsc.edu

Pharmacist involvement in managing medications for opioid use disorder (MOUD), such as buprenorphine, has been previously shown feasible and has the potential for nationwide scalability. To maximize impact, such models must make use of scope of practice enhancing authorities, such as collaborative practice agreements. This project will: (1) engage community stakeholders to co-develop a model collaborative practice agreement for pharmacist-managed buprenorphine care and (2) identify existing legal authorities and advocacy opportunities to expand pharmacist-managed buprenorphine care in all 50 states. This will be accomplished using a community-engaged research approach as well as two 50-state reviews of state statutes, rules, and adopted policies or existing guidelines related to pharmacist-managed MOUD, particularly focused on pharmacist prescriptive authority and, separately, existing state-level legal barriers to MOUD care.

Related Resources